Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Versant Venture Capital VI, L.P., along with affiliated entities, reported selling 191,376 shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) common stock on July 10, 2025. The shares were sold at a price of $34.00, totaling $6,506,784. The transaction comes amid LENZ’s strong market performance, with the stock showing a 65% return over the past year and a 55% gain in the last six months. According to InvestingPro analysis, the company currently appears overvalued at its market capitalization of $949 million.
Following the transaction, Versant Venture Capital VI, L.P. directly holds 1,575,899 shares of Lenz Therapeutics. In addition, Versant Venture Capital VII, L.P. holds 1,047,912 shares, and Versant Vantage II, L.P. holds 842,162 shares indirectly. The reporting owners disclaim beneficial ownership of these indirectly held shares except to the extent of their respective pecuniary interests. For deeper insights into LENZ’s valuation and 12+ additional exclusive tips, visit InvestingPro.
In other recent news, Lenz Therapeutics announced an exclusive licensing agreement with Laboratoires Théa for the commercialization of its presbyopia treatment, LNZ100, in Canada. The deal could bring Lenz over $70 million in milestone payments, alongside tiered royalties on net sales. This follows another agreement with Lotus Pharmaceutical (TADAWUL:2070) for the distribution of LNZ100 in the Republic of Korea and select Southeast Asian countries, potentially earning Lenz up to $125 million. These strategic partnerships aim to leverage the commercial infrastructure of Théa and Lotus to bring LNZ100 to market upon approval.
Additionally, Citi analysts maintained a Buy rating on Lenz Therapeutics, setting a $45 price target. They noted the potential FDA approval of LNZ100 by August 8, 2025, as a significant milestone. Lenz recently reported a successful Late Cycle FDA meeting with no major review issues, supporting the analysts’ positive outlook. William Blair also reiterated its Outperform rating, citing LNZ100’s strong clinical trial results as a potential blockbuster opportunity. These developments come as Lenz continues to prepare for the commercialization phase of its eye treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.